Beyond Celiac Investments Supports RheumaGen in Celiac Disease Treatment Innovations Beyond Celiac Investments has announced vital funding for RheumaGen to develop innovative treatments for celiac disease, focusing on gene editing technologies.

Beyond Celiac Investments Supports RheumaGen in Celiac Disease Treatment Innovations #USA #Philadelphia #gene_therapy #RheumaGen #Celiac_Disease

RheumaGen Secures Funding from Beyond Celiac Investments to Enhance Celiac Disease Treatments RheumaGen has announced a significant funding agreement with Beyond Celiac Investments to advance innovative treatments for celiac disease through its gene therapy platform.

RheumaGen Secures Funding from Beyond Celiac Investments to Enhance Celiac Disease Treatments #United_States #gene_therapy #Aurora #RheumaGen #Celiac_Disease

RheumaGen Unveils Innovative HLA Gene-Editing Breakthrough at ACR Convergence 2025 RheumaGen, Inc. announced its revolutionary HLA gene-editing research at ACR Convergence 2025, targeting autoimmune diseases using anchor-position editing techniques.

RheumaGen Unveils Innovative HLA Gene-Editing Breakthrough at ACR Convergence 2025 #United_States #Aurora #RheumaGen #Autoimmune_Diseases #HLA_gene-editing

RheumaGen and SiVEC Biotechnologies Partner to Transform Autoimmune Disease Treatments with Gene Editing RheumaGen and SiVEC Biotechnologies announce a groundbreaking partnership to develop gene-editing therapies aimed at curing common autoimmune diseases.

RheumaGen and SiVEC Biotechnologies Partner to Transform Autoimmune Disease Treatments with Gene Editing #USA #RheumaGen #Aurora,_Colorado #gene-editing #SiVEC

RheumaGen Set to Present Breakthrough HLA Gene-Editing Research at ACR Convergence 2025 RheumaGen, Inc. will present innovative HLA gene-editing data for autoimmune diseases at ACR Convergence 2025, highlighting its potential impact.

RheumaGen Set to Present Breakthrough HLA Gene-Editing Research at ACR Convergence 2025 #USA #Aurora #RheumaGen #rheumatoid_arthritis #HLA_Gene_Editing

RheumaGen, Inc. Secures $15 Million Series A to Transform Autoimmune Treatment with Gene Editing RheumaGen, Inc. has launched with $15 million in Series A financing, aiming to develop innovative HLA gene-editing therapies targeting major autoimmune diseases, specifically rheumatoid arthritis.

RheumaGen, Inc. Secures $15 Million Series A to Transform Autoimmune Treatment with Gene Editing #United_States #Aurora #Autoimmune_Disease #Gene_Editing #RheumaGen